Detalles de la búsqueda
1.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Am J Hematol
; 99(4): 774-779, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38343062
2.
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Am J Hematol
; 98(10): 1588-1597, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37470365
3.
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Am J Hematol
; 98(10): 1579-1587, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37466271
4.
Construction of poly (ionic liquid)-derived gold/silver alloy@nitrogen-doped carbon shell and its application for ratiometric electrochemical detection of nitric oxide.
Talanta
; 272: 125839, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38428134
5.
Controllable preparation of silver-doped hollow carbon spheres and its application as electrochemical probes for determination of glycated hemoglobin.
Bioelectrochemistry
; 152: 108450, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37116231
6.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers.
Front Pharmacol
; 11: 604314, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33536914
Resultados
1 -
6
de 6
1
Próxima >
>>